Myriad Genetics (MYGN) Misses Q2 EPS by 8c, Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Myriad Genetics (MYGN) PT Lowered to $19 at Jefferies
February 7, 2020 9:14 AM ESTJefferies analyst Brandon Couillard lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $19.00 (from $23.00) while maintaining a Hold rating.
The analyst commented, "We expect MYGN to open sharply lower (down >20% after-hours) after another 2Q miss, ~50% cut to '20 EPS guide & abrupt CEO... More
Myriad Genetics (MYGN) announces Mark Capone has resigned as President and CEO
February 6, 2020 4:14 PM ESTMyriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member of the Companys Board of Directors, effective immediately. Mr. Capone will remain available to the Company to assist in this transition.
As we position Myriad for its next phase of growth and... More
